YAP1 and glioblastoma: Moreover, GSEA for the VC-Resist geneset of a recently published RNA-seq dataset of three GBM preclinical models treated with verteporfin—a well-recognized and clinically approved inhibitor of YAP50 – indicated that therapeutic inhibition of the YAP/TAZ pathway strongly reduces VC-Resist cell state (Fig. 9I).